Literature DB >> 2656336

A new phase of insulin secretion. How will it contribute to our understanding of beta-cell function?

G M Grodsky1.   

Abstract

Although initially described two decades ago, biphasic insulin secretion has gradually been understood to reflect beta-cell rate sensitivity, be important in minimizing overinsulinization in normal individuals, be defective in non-insulin-dependent diabetes mellitus (NIDDM), and be useful as an early predictor in prediabetic individuals. Recently, a third phase of insulin secretion has been observed in fully in vitro islets or pancreatic preparations. This phase is characterized as a spontaneous decline of secretion (desensitization) during 24 h of sustained exposure to glucose or other secretagogues and does not appear to be simply an artifact of in vitro preparations. The impaired secretion is localized to the final release process in that neither glucose-stimulated proinsulin synthesis nor its conversion to insulin is affected. The mechanisms responsible for the third phase of reduced secretion are unknown. Kinetic evidence suggests it is not caused by emptying of a single finite insulin storage compartment but does not exclude the possibility that the decreased release reflects depletion of threshold-sensitive beta-cells recruited at a given secretagogue level. Alternatively, the third phase may reflect inhibition of a priming or terminal insulin-release process by metabolic feedback. Because several secretagogues cause similar third-phase impaired release, even in the absence of glucose, desensitization probably occurs at a common fundamental site in the secretory site (e.g., calcium metabolism). Preliminary studies indicate the third phase is not the result of a paracrine effect by other islet hormones or of a change in muscarinic regulation. Whether other neurologic effectors are involved requires further investigation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2656336     DOI: 10.2337/diab.38.6.673

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  18 in total

1.  Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.

Authors:  R P Robertson; H J Zhang; K L Pyzdrowski; T F Walseth
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

2.  RyR channels and glucose-regulated pancreatic beta-cells.

Authors:  Xuan Zhan; Lijian Yang; Ming Yi; Ya Jia
Journal:  Eur Biophys J       Date:  2008-02-01       Impact factor: 1.733

3.  Chronic exposure to glibenclamide impairs insulin secretion in isolated rat pancreatic islets.

Authors:  D Gullo; A M Rabuazzo; M Vetri; C Gatta; C Vinci; M Buscema; R Vigneri; F Purrello
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

4.  Time-dependent effects of cholinergic stimulation on beta cell responsiveness.

Authors:  W S Zawalich; K C Zawalich; G G Kelley
Journal:  Pflugers Arch       Date:  1996-08       Impact factor: 3.657

5.  Hyperglycemia-induced B cell toxicity. The fate of pancreatic islets transplanted into diabetic mice is dependent on their genetic background.

Authors:  O Korsgren; L Jansson; S Sandler; A Andersson
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 6.  Emerging treatments for post-transplantation diabetes mellitus.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

7.  Role of protein kinase C and Ca2+ in glucose-induced sensitization/desensitization of insulin secretion.

Authors:  P Thams
Journal:  Experientia       Date:  1991-12-01

8.  Biphasic insulin secretion from freshly isolated or cultured, perifused rodent islets: comparative studies with rats and mice.

Authors:  Walter S Zawalich; Hanae Yamazaki; Kathleen C Zawalich
Journal:  Metabolism       Date:  2008-01       Impact factor: 8.694

Review 9.  Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.

Authors:  James F McLeod
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Adaptation of ovine fetal pancreatic insulin secretion to chronic hypoglycaemia and euglycaemic correction.

Authors:  Sean W Limesand; William W Hay
Journal:  J Physiol       Date:  2002-10-04       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.